Showing 1,101 - 1,120 results of 1,132 for search '"immunosuppressant"', query time: 0.07s Refine Results
  1. 1101

    Interactive effects of triploidy induction and culture densities on growth performance and stress, immune, and metabolic responses in juvenile rainbow trout (Oncorhynchus mykiss) by Roghayeh Mahmoudi, Mahdi Naderi, Hakimeh Dopeikar, Seyed Ali Khorasaninasab, Seyed Hadi Seyedalhosseini

    Published 2025-03-01
    “…Thus, rainbow trout chronically exposed to high culture density (50 kg/m3) showed signs of immunosuppression. Chronic high density stress exhibited harmful impacts on liver functions, resulting in elevated activities of serum ALT and AST enzymes (P < 0.05). …”
    Get full text
    Article
  2. 1102

    Mycotoxilogical monitoring. Part 2. Wheat, barley, oat and maize grain by G. P. Kononenko, A. A. Burkin, Ye. V. Zotova

    Published 2020-06-01
    “…High prevalence of alternariol and emodin known as “diarrhea factor” as well as maize grain contamination with mycophenolic acid (mycotoxin having an immunosuppressive effect) are for the first time reported in this paper. …”
    Get full text
    Article
  3. 1103

    Serological Profile of Anti-<i>Toxoplasma gondii</i> Antibodies in Liver Transplant Recipients by Gabriella Beltrame Pintos, Francielly Camilla Bazílio Laurindo Pires, Nathália Zini, Rita Cássia Martins Alves da Silva, Francisco Inaldo Mendes Silva Junior, Renato Ferreira da Silva, Tainara Souza Pinho, Luiz Carlos de Mattos, Cinara Cássia Brandão

    Published 2025-01-01
    “…The liver has emerged as a frequent transplanted organ in which the transmission of <i>T. gondii</i> can occur between seropositive donors and seronegative recipients. Allied with immunosuppressive therapy, the presence of latent infection in recipients elevates the risk of severe toxoplasmosis. …”
    Get full text
    Article
  4. 1104
  5. 1105

    Proteasome inhibition enhances oncolytic reovirus therapy in multiple myeloma independently of its direct cytotoxic effects by Ada Alice Dona, Theophilus Tandoh, Lokesh Nigam, Mahmoud Singer, Enrico Caserta, Mariam Murtadha, Yinghui Zhu, Milad Moloudizargari, Preeti Sharma, Ottavio Napolitano, Janet Winchester, Arnab Chowdhury, Alex Pozhitkov, James F. Sanchez, Hawa Vahed, Guido Marcucci, Matt Coffey, Gerard Nuovo, Douglas W. Sborov, Flavia Pichiorri, Craig C Hofmeister

    Published 2025-01-01
    “…Conclusions Although characterized as immunosuppressive drugs, PIs improved RV delivery to MM cells but also enhanced anti-MM efficacy through immune-mediated killing of myeloma cells, independently of their PI sensitivity. …”
    Get full text
    Article
  6. 1106

    Molecular underpinnings of exceptional response in primary malignant melanoma of the esophagus to anti-PD-1 monotherapy by Yu Chen, Xuan Wang, Jie Dai, Li Zhou, Xuefeng Xia, Jun Guo, Xue Bai, Lu Si, Bixia Tang, Chuanliang Cui, Xiaoting Wei, Xinan Sheng, Siming Li, Zhihong Chi, Lili Mao, Bin Lian, Xieqiao Yan, Yan Kong, Caili Li, Xuan Gao, Lirui Tang, Linzi Sun, Zhonghui Qi, Zelong Xu

    Published 2023-01-01
    “…Transcriptome analysis revealed that, compared with NEMM, PMME displayed more significant proliferation and inflammatory features with higher expression of genes related to antigen presentation and differentiation, and a less immunosuppressive signature with lower expression of inhibitory immune checkpoints and dedifferentiation-related genes. …”
    Get full text
    Article
  7. 1107
  8. 1108

    TIGIT inhibitor M6223 as monotherapy or in combination with bintrafusp alfa in patients with advanced solid tumors: a first-in-human, phase 1, dose-escalation trial by Wei Gao, Ping Hu, Aung Naing, Meredith McKean, Anthony Tolcher, Lillian L Siu, Keyvan Tadjalli-Mehr, Anja Victor, Emilia Richter, Marco A F Nogueira Filho, Thomas Kitzing, Stephan Gleicher, Daniel Holland

    Published 2025-02-01
    “…Bintrafusp alfa (BA) is a bifunctional fusion protein that simultaneously blocks nonredundant immunosuppressive TGF-β and PD-(L)1 pathways.Methods This first-in-human, dose-escalation study in patients with advanced solid tumors (N=58; aged ≥18 years, ECOG PS≤1) evaluated M6223 alone (Part 1A, n=40; M6223 10–2400 mg every 2 weeks, n=32; M6223 2400 mg every 3 weeks, n=8) or with BA (Part 1B, n=18; M6223 300–1600 mg with BA 1200 mg; both every 2 weeks, intravenous). …”
    Get full text
    Article
  9. 1109

    Integrating single-cell RNA-Seq and bulk RNA-Seq data to explore the key role of fatty acid metabolism in hepatocellular carcinoma by Hua Dai, Xin Tao, Yuansen Shu, Fanrong Liu, Xiaoping Cheng, Xiushen Li, Bairui Shu, Hongcheng Luo, XuXiang Chen, Zhaorui Cheng

    Published 2025-01-01
    “…Elevated expression of PTGES3 was linked to immunosuppressive cascades, diminished responsiveness to immunotherapy, and inferior overall survival outcomes. …”
    Get full text
    Article
  10. 1110
  11. 1111

    Physiology and Pathophysiology of Marathon Running: A narrative Review by Lorin Braschler, Pantelis T. Nikolaidis, Mabliny Thuany, Daniela Chlíbková, Thomas Rosemann, Katja Weiss, Matthias Wilhelm, Beat Knechtle

    Published 2025-01-01
    “…A marathon is often accompanied by an acute inflammatory response with transient immunosuppression, making runners susceptible to infections. …”
    Get full text
    Article
  12. 1112

    COVID-19 pandemic and vaccination rate in patients with psoriasis treated with biologics: A single center experience by Milčić Danijela, Malinić Marija, Ćirković Anđa, Krupniković Doroteja, Milinković-Srećković Mirjana

    Published 2024-01-01
    “…The coronavirus disease 2019 (COVID-19) raised widespread concern for patients with psoriasis treated with immunosuppressive drugs, especially biologics. Even though there was no data at the beginning of the pandemic on the efficacy and safety of vaccines against COVID-19 in patients with psoriasis treated with biologics, the National Psoriasis Foundation (United States of America) recommended vaccination in these patients. …”
    Get full text
    Article
  13. 1113

    Clinical course, management and outcomes of COVID-19 in HIV-infected renal transplant recipients: A case series by L Bertels, K Manning, A Redd, T du Toit, Z Barday, E Muller

    Published 2024-04-01
    “…HIV‐infected kidney transplant recipients with COVID‐19 are at increased risk of acute illness and death owing to their underlying comorbidities and chronic immunosuppression. Objectives. To describe the incidence, clinical presentation and course of COVID‐19, vaccination status, and SARS‐CoV‐2 antibody positivity rate among HIV‐infected‐to‐HIV‐infected kidney transplant recipients in South Africa (SA). …”
    Get full text
    Article
  14. 1114

    Diagnostic Effectiveness of Transforming Growth Factor Beta 1 in Assessing the Risk of Developing Graft Dysfunction in Liver Recipient Children by R. M. Kurabekova, O. M. Tsiroulnikova, I. E. Pashkova, A. G. Olefirenko, O. E. Gichkun, L. V. Makarova, R. A. Monakhov, P. O. Shevchenko

    Published 2019-06-01
    “…Transforming growth factor beta 1 (TGF-β1) is a pleiotropic cytokine with a profibrogenic and immunosuppressive effect that can have a definite effect on the liver transplant functioning.Aim. …”
    Get full text
    Article
  15. 1115

    Circulating Th1 and Th2 Subset Accumulation Kinetics in Septic Patients with Distinct Infection Sites: Pulmonary versus Nonpulmonary by Ming Xue, Yuying Tang, Xu Liu, Mingyuan Gu, Jianfeng Xie, Ling Liu, Yingzi Huang, Fengmei Guo, Yi Yang, Haibo Qiu

    Published 2020-01-01
    “…Persistent peripheral CD4+T cell differentiation towards T helper (Th)2 rather than Th1 has been proved to be related to immunosuppression and poor prognosis in sepsis. However, it is unclear whether these circulating Th1 and Th2 subtype accumulations differed in septic populations of distinct infection sites and presented different associations with outcomes among patients with pulmonary versus nonpulmonary sepsis. …”
    Get full text
    Article
  16. 1116
  17. 1117

    Incidence and contributing factors of dementia among people living with HIV in British Columbia, Canada, from 2002 to 2016: a retrospective cohort study by Rolando Barrios, Julio S G Montaner, Silvia Guillemi, Ni Gusti Ayu Nanditha, Viviane D Lima, Thomas L Patterson, Fidel Vila-Rodriguez, William G Honer, Jason Trigg, Hasan Nathani, Sara Shayegi-Nik, Weijia Yin, Alejandra Fonseca, Bronhilda T Takeh

    Published 2024-04-01
    “…Initiating ART in 2005–2010 (versus&lt;2000) produced an aCSH of 0.51 (95% CI: 0.30 to 0.89).Conclusions We demonstrated the negative role of immunosuppression and inflammation on the incidence of dementia among PLWH. …”
    Get full text
    Article
  18. 1118

    29 m6A-RNA Methylation (Epitranscriptomic) Regulators Are Regulated in 41 Diseases including Atherosclerosis and Tumors Potentially via ROS Regulation – 102 Transcriptomic Dataset... by Ming Liu, Keman Xu, Fatma Saaoud, Ying Shao, Ruijing Zhang, Yifan Lu, Yu Sun, Charles Drummer, Li Li, Sheng Wu, Satya P. Kunapuli, Gerard J. Criner, Jianxin Sun, Huimin Shan, Xiaohua Jiang, Hong Wang, Xiaofeng Yang

    Published 2022-01-01
    “…We performed a database mining on 102 transcriptomic datasets for the expressions of 29 m6A-RNA methylation (epitranscriptomic) regulators (m6A-RMRs) in 41 diseases and cancers and made significant findings: (1) a few m6A-RMRs were upregulated; and most m6A-RMRs were downregulated in sepsis, acute respiratory distress syndrome, shock, and trauma; (2) half of 29 m6A-RMRs were downregulated in atherosclerosis; (3) inflammatory bowel disease and rheumatoid arthritis modulated m6A-RMRs more than lupus and psoriasis; (4) some organ failures shared eight upregulated m6A-RMRs; end-stage renal failure (ESRF) downregulated 85% of m6A-RMRs; (5) Middle-East respiratory syndrome coronavirus infections modulated m6A-RMRs the most among viral infections; (6) proinflammatory oxPAPC modulated m6A-RMRs more than DAMP stimulation including LPS and oxLDL; (7) upregulated m6A-RMRs were more than downregulated m6A-RMRs in cancer types; five types of cancers upregulated ≥10 m6A-RMRs; (8) proinflammatory M1 macrophages upregulated seven m6A-RMRs; (9) 86% of m6A-RMRs were differentially expressed in the six clusters of CD4+Foxp3+ immunosuppressive Treg, and 8 out of 12 Treg signatures regulated m6A-RMRs; (10) immune checkpoint receptors TIM3, TIGIT, PD-L2, and CTLA4 modulated m6A-RMRs, and inhibition of CD40 upregulated m6A-RMRs; (11) cytokines and interferons modulated m6A-RMRs; (12) NF-κB and JAK/STAT pathways upregulated more than downregulated m6A-RMRs whereas TP53, PTEN, and APC did the opposite; (13) methionine-homocysteine-methyl cycle enzyme Mthfd1 downregulated more than upregulated m6A-RMRs; (14) m6A writer RBM15 and one m6A eraser FTO, H3K4 methyltransferase MLL1, and DNA methyltransferase, DNMT1, regulated m6A-RMRs; and (15) 40 out of 165 ROS regulators were modulated by m6A eraser FTO and two m6A writers METTL3 and WTAP. …”
    Get full text
    Article
  19. 1119

    Drug-drug interaction between ensitrelvir and tacrolimus in a patient undergoing treatment for COVID-19: a case report by Yuki Miyata, Ryo Yamaguchi, Takehito Yamamoto, Toshiyuki Kishida, Kazuhiko Ikeuchi, Hiroaki Harada, Takeya Tsutsumi, Keishi Fujio, Tappei Takada

    Published 2025-01-01
    “…Tacrolimus (TAC) is a widely used immunosuppressive agent whose blood level can increase significantly due to the inhibition of cytochrome P450 3A (CYP3A) and P-glycoprotein by nirmatrelvir/ritonavir. …”
    Get full text
    Article
  20. 1120

    Impact of donor CYP3A5 genotype on pharmacokinetics of tacrolimus in South African paediatric liver transplant patients by C Wheeler, C Masimirembwa, B Mthembu, J Botha, J Scholefield, J Fabian

    Published 2024-04-01
    “…In the paediatric liver transplant programme in Johannesburg, South Africa (SA), tacrolimus is the calcineurin inhibitor of choice, comprising an essential component of the immunosuppression regimen. It is characterised by a narrow therapeutic index and wide interpatient variability, necessitating therapeutic drug monitoring of whole-blood concentrations. …”
    Get full text
    Article